Dashboard
Manage Tickers

GTHXG1 Therapeutics, Inc.

Nasdaq g1therapeutics.com


$ 4.22 $ -0.09 (-2.09 %)    

Thursday, 23-May-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -7.39 (-1.6 %)
DIA $ 398.57 $ -5.95 (-1.5 %)
SPY $ 530.36 $ -3.85 (-0.73 %)
TLT $ 91.26 $ -0.59 (-0.64 %)
GLD $ 225.37 $ -4.39 (-1.99 %)
$ 4.22
$ 4.30
$ 4.20 x 200
$ 4.22 x 400
$ 4.15 - $ 4.32
$ 1.08 - $ 6.14
1,003,820
na
224.86M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-21-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
05/22/2024 16:15:27

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

hc-wainwright--co-reiterates-buy-on-g1-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on G1 T...
05/22/2024 12:38:45

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

g1-therapeutics-shares-are-trading-higher-after-the-company-and-deimos-biosciences-announced-a-licensing-agreement-for-lerociclib-for-radioprotective-uses
G1 Therapeutics shares are trading higher ...
05/22/2024 10:36:06

g1-therapeutics-and-deimos-biosciences-announced-a-global-licensing-agreement-excluding-the-asia-pacific-region-for-lerociclib-for-radioprotective-uses-g1-is-expected-to-receive-10-of-deimos-biosciences-shares-in-addition-to-a-20-sales-based-royalty
G1 Therapeutics And Deimos Biosciences Ann...
05/22/2024 10:33:00

whats-going-on-with-g1-therapeutics-stock
What's Going On With G1 Therapeutics Stock?
05/09/2024 18:24:53

According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics.  According to the r...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

watching-g1-therapeutics-traders-circulate-ma-blog-suggesting-company-rumored-to-have-a-cvr-aspect-that-could-value-the-company-at-between-12-14share
Watching G1 Therapeutics; Traders Circulat...
05/09/2024 14:04:11

hc-wainwright--co-reiterates-buy-on-g1-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on G1 T...
05/02/2024 17:37:50

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

evaluating-g1-therapeutics-insights-from-5-financial-analysts
Evaluating G1 Therapeutics: Insights From ...
05/01/2024 18:00:58

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
05/01/2024 16:05:40

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

g1-therapeutics-reaffirms-2024-net-cosela-revenue-guidance-of-60m-70m-expects-cash-runway-to-extend-into-q3-of-2025
G1 Therapeutics Reaffirms 2024 Net COSELA ...
05/01/2024 10:33:57

G1's product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S.

g1-therapeutics-q1-2024-gaap-eps-020-inline-sales-14476m-miss-15259m-estimate
G1 Therapeutics Q1 2024 GAAP EPS $(0.20), ...
05/01/2024 10:31:59

G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is ...

g1-therapeutics-and-pepper-bio-announced-a-global-licensing-agreement-excluding-the-asia-pacific-region-for-lerociclib-for-all-indications-except-for-certain-radioprotectant-uses
G1 Therapeutics And Pepper Bio Announced A...
05/01/2024 10:26:52

breaking-down-g1-therapeutics-5-analysts-share-their-views
Breaking Down G1 Therapeutics: 5 Analysts ...
04/12/2024 14:02:12

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
04/12/2024 10:00:06

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/08/2024 12:09:45

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
02/28/2024 17:31:10

forecasting-the-future-5-analyst-projections-for-g1-therapeutics
Forecasting The Future: 5 Analyst Projecti...
02/28/2024 17:01:01

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
02/28/2024 16:45:12

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

g1-therapeutics-ended-2023-with-cash-cash-equivalents-and-marketable-securities-of-822m-with-cash-runway-expected-into-2025
G1 Therapeutics Ended 2023 With Cash, Cash...
02/28/2024 11:39:02

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION